EUROAPI targets North American compounding market through MEDISCA as peptide strategy expands

EUROAPI S.A. (Euronext Paris: EAPI), the French active pharmaceutical ingredient manufacturer, is extending its commercial reach into North America’s pharmaceutical compounding market through a strategic partnership with Canada-based MEDISCA. Announced on October 7, 2026, the agreement establishes MEDISCA as EUROAPI’s first strategic distribution partner specifically focused on supplying European-manufactured active pharmaceutical ingredients to the region’s compounding sector, with exclusive arrangements covering selected ingredients. The companies also intend to explore peptide collaboration, additional pharmaceutical ingredients and expansion into other markets, creating a potential longer-term commercial platform beyond the initial distribution relationship. For EUROAPI, the agreement arrives as its core API business faces declining sales and restructuring pressures, making the conversion of new distribution relationships into profitable, recurring orders particularly important.

How will the MEDISCA and EUROAPI partnership change pharmaceutical API distribution in North America?

The partnership combines EUROAPI’s pharmaceutical manufacturing capabilities with MEDISCA’s established distribution network, product knowledge and relationships across the pharmaceutical compounding industry. MEDISCA will provide a commercial route for selected EUROAPI-manufactured ingredients into North America, while EUROAPI will support the relationship with available technical and regulatory information associated with those products. The commercial structure includes exclusive supply arrangements for certain APIs, although the companies have not identified the specific ingredients, disclosed committed volumes or published the financial terms. The exclusivity therefore applies to selected products within the partnership rather than EUROAPI’s entire API portfolio or all of its North American distribution activities.

For MEDISCA, the relationship strengthens a sourcing model built around direct manufacturer relationships, documentation and technical support. The company, established in 1989, operates across pharmaceutical compounding, analytical testing, education, formulation services and the distribution of ingredients and equipment. Its wider product offering includes more than 2,000 products and a library of over 10,000 proprietary and customised medication formulas, giving it an established commercial infrastructure through which additional APIs may be introduced. Bringing a European manufacturer into this network could provide greater visibility over ingredient origin, specifications and manufacturing documentation, although product availability and customer adoption will determine the scale of the benefit.

The value of the arrangement also depends on the distinction between manufacturing an API and supplying it successfully to a compounding business. Pharmaceutical compounders need ingredients supported by appropriate analytical information, traceable supply chains and documentation relevant to their intended applications. EUROAPI’s role is to provide manufacturing expertise and available technical information, while MEDISCA contributes distribution capabilities and knowledge of customer requirements. This division of responsibilities could reduce commercial friction if the companies can align product specifications, quality documentation, delivery schedules and customer demand without materially increasing distribution costs.

MEDISCA Chief Business Officer Peng Li identified EUROAPI’s manufacturing expertise, quality systems and sustainability capabilities as important elements of the relationship. EUROAPI Chief Commercial Officer Frederic Robert, meanwhile, indicated that MEDISCA’s understanding of pharmaceutical compounding could help the manufacturer expand its reach and develop opportunities in peptides. Both companies have framed the relationship as a platform for future collaboration rather than a distribution arrangement restricted permanently to the initial ingredient portfolio. However, the announcement does not establish a minimum purchasing commitment, guaranteed revenue stream or dedicated manufacturing-capacity reservation.

Why is MEDISCA expanding direct manufacturer partnerships as pharmaceutical compounding becomes more complex?

The EUROAPI agreement follows another manufacturing partnership announced by MEDISCA earlier in 2026, suggesting a broader strategy of strengthening its pharmaceutical ingredient sourcing network. In May, MEDISCA entered a relationship with dsm-firmenich to improve access to pharmaceutical-grade vitamin APIs for the US compounding market. That arrangement emphasised ingredients manufactured within established European pharmaceutical quality environments and supported by technical documentation. The subsequent EUROAPI partnership broadens this manufacturer-led approach and creates additional opportunities across ingredients that extend beyond the vitamin category.

Direct relationships with manufacturers can provide distributors with stronger supply-chain visibility than procurement through multiple intermediaries. They may improve coordination around specifications, change-control notifications, manufacturing documentation and the handling of quality-related questions raised by customers. These capabilities can become commercially valuable when compounders need consistency across repeated orders or when manufacturers adjust production schedules and product portfolios. Nevertheless, direct sourcing does not eliminate the need for supplier qualification, independent quality controls or compliance with destination-market regulations.

The business opportunity is partly linked to the increasing complexity of pharmaceutical compounding services. Personalised formulations may require different strengths, dosage forms or ingredient combinations to address specific patient needs when suitable commercially available medicines cannot be used. Compounding businesses consequently depend on a broad range of ingredients, reliable sourcing and adequate technical support, rather than access to manufacturing capacity alone. MEDISCA’s combination of supply, formulation knowledge, laboratory services and education positions it to provide several components of that operating environment, although the newly announced partnership concerns selected APIs rather than a comprehensive outsourcing arrangement.

The companies also intend to work together on customer initiatives, training and commercial development activities. Such cooperation could help EUROAPI understand which ingredients face recurring demand and where its existing manufacturing capabilities align with compounding requirements. For MEDISCA, direct manufacturing relationships may create opportunities to differentiate its API offering through documentation, consistency and service rather than relying solely on price competition. Whether that translates into stronger margins will depend on procurement economics, inventory requirements and the competitiveness of alternative suppliers.

Why does peptide collaboration create a bigger opportunity but greater uncertainty for MEDISCA and EUROAPI?

The peptide component gives the partnership additional strategic relevance because MEDISCA had already established a dedicated global peptide division before announcing the EUROAPI relationship. On September 17, 2026, the company launched MEDISCA Peptides to develop an integrated business covering API-grade peptide sourcing, formulation expertise, analytical services, technical support and related pharmaceutical infrastructure. MEDISCA described the division as part of a multiyear effort to expand its peptide portfolio and build relationships with specialised manufacturing partners. The EUROAPI agreement follows that initiative, potentially adding another manufacturing relationship to the company’s developing peptide ecosystem.

EUROAPI brings experience in pharmaceutical ingredient production, complex chemical synthesis and contract development and manufacturing services. Its existing capabilities could support future cooperation involving technically demanding molecules, provided the companies identify suitable products and establish the necessary commercial, manufacturing and regulatory arrangements. Peptides can present particular manufacturing and analytical challenges involving impurities, product characterisation, consistency and stability, making manufacturer expertise an important component of supply-chain quality. The partnership announcement, however, does not identify any peptide API that EUROAPI has committed to manufacture or MEDISCA has committed to distribute under a specific new programme.

The growing commercial visibility of peptide-based medicines also needs to be separated from the legal market for compounded peptide products. Pharmaceutical interest in peptides spans several therapeutic areas, but not every peptide ingredient is eligible for pharmaceutical compounding under US law. The applicable requirements depend on the identity of the substance, the type of compounding facility, the intended drug product and the relevant regulatory conditions. A manufacturing relationship may establish a potential source of high-quality ingredients, but it cannot independently create legal authorisation to compound or market medicines containing those substances.

This regulatory limitation is especially relevant because MEDISCA has identified telehealth, wellness and personalised care among the areas influencing the compounding market. Those sectors may provide commercial demand signals, but demand does not establish that every proposed compounded treatment is legally permissible or clinically appropriate. The partnership’s peptide opportunity should therefore be viewed as an area for evaluation rather than an announced product launch, established revenue pipeline or commitment to supply any particular weight-management ingredient. Its commercial scale will become clearer only when the companies disclose eligible products, manufacturing arrangements and actual customer demand.

Can MEDISCA help EUROAPI offset falling API sales and improve its restructuring economics?

EUROAPI’s latest half-year financial results provide the clearest explanation for the commercial importance of expanding distribution. The company reported net sales of €356.5 million for the six months ended June 30, 2026, down 13.5% from €412.1 million in the corresponding period of 2025. Its API Solutions business experienced a steeper decline of 19.3%, with revenue falling from €299.7 million to €241.9 million. The company attributed part of this contraction to planned product discontinuations under its portfolio optimisation programme, alongside weaker demand in certain existing ingredient categories.

The reduction in API Solutions revenue was not evenly distributed across customer groups. Sales to Sanofi fell to €63.6 million from €99.6 million on a comparable customer-allocation basis, while sales to other API Solutions customers decreased to €178.3 million from €200.1 million. EUROAPI disclosed that planned product discontinuations produced a €13 million negative year-on-year impact on first-half API sales. A new North American distribution channel could help the company develop business outside existing large customer relationships, although the extent of any revenue contribution from MEDISCA cannot currently be quantified.

The company’s Contract Development and Manufacturing Organization activities performed comparatively better during the period, recording sales growth of 2% to €114.7 million. Commercial-stage manufacturing represented the overwhelming majority of those revenues, while development projects accounted for a smaller proportion. This contrast illustrates why broadening the customer base for existing APIs could be commercially useful alongside investment in more complex contract manufacturing opportunities. Distribution partnerships may offer access to additional buyers without requiring the same development cycle as a completely new molecule, but the ability to serve smaller or more fragmented customers profitably remains an important consideration.

Profitability presents a more demanding test of EUROAPI’s transformation. First-half core earnings before interest, taxes, depreciation and amortisation fell to €20.7 million from €39.5 million, while the corresponding margin declined from 9.6% to 5.8%. The company reported a net loss of €141.5 million, compared with a loss of €28.5 million a year earlier, reflecting restructuring charges, impairments and operating pressures. These results suggest that additional commercial agreements will be most valuable if they improve manufacturing utilisation, product mix or contribution margins rather than simply increasing sales volumes.

EUROAPI’s balance-sheet and cash-flow position reinforces the need for disciplined execution. The company moved from a net cash position of €68.2 million at the end of December 2025 to net debt of €37.9 million at June 30, 2026, while cash flow before financing activities was negative €103.4 million during the first half. Management also adjusted its full-year core EBITDA margin outlook to approximately 6%, partly because of the adverse cost impact of Hungarian forint appreciation. The MEDISCA agreement offers a potential commercial improvement, but no disclosed financial commitment supports treating it as an immediate remedy for these operating and cash-flow pressures.

How does EUROAPI’s FOCUS-27 restructuring influence its ability to serve new pharmaceutical customers?

The distribution partnership is unfolding alongside EUROAPI’s FOCUS-27 transformation programme, which aims to simplify its operations, rationalise its manufacturing footprint and improve competitiveness. The company has been reducing exposure to selected lower-priority products while directing resources toward activities it considers more sustainable or commercially attractive. This strategy can produce a temporary reduction in revenue as discontinued products leave the portfolio, even where management expects the revised business mix to support better long-term profitability. Adding distribution channels could help EUROAPI identify demand for retained products and improve the commercial productivity of its manufacturing assets.

One major restructuring milestone was the July 29, 2026 agreement to sell EUROAPI Italy S.R.L., the subsidiary operating its Brindisi manufacturing site, to Huvepharma EOOD. The announced transaction assigns an enterprise value of €5 million to the business and includes EUROAPI commitments totalling €60 million over a two-year transition period to support operations, capital expenditure and transformation activities. Completion was expected before the end of 2026, meaning the transaction should not be treated as already finalised merely because a share purchase agreement has been signed. The associated financial commitments also illustrate that restructuring can require substantial near-term resources before any longer-term benefits are realised.

For the MEDISCA relationship, the relevant manufacturing consideration is whether EUROAPI can reliably supply the selected APIs through its continuing production network. A distribution partnership becomes economically attractive when new demand can be served at suitable margins without creating disproportionate inventory, documentation or logistics costs. The compounding market may involve purchasing patterns different from those of large pharmaceutical manufacturers, particularly when orders are distributed across a wider range of customers and product quantities. MEDISCA’s established distribution infrastructure could help bridge that operational difference, but the companies have not disclosed enough information to determine the financial model.

What do FDA compounding rules mean for the new EUROAPI and MEDISCA ingredient supply relationship?

The US Food and Drug Administration’s framework for pharmaceutical compounding creates different requirements for traditional compounders operating under Section 503A and registered outsourcing facilities operating under Section 503B of the Federal Food, Drug, and Cosmetic Act. Under Section 503A, the permitted use of bulk drug substances depends on conditions involving applicable pharmacopeial standards, components of approved drugs or substances included on the relevant compounding list. Section 503B imposes separate restrictions tied to clinical-need listings and certain drug-shortage circumstances, alongside applicable interim regulatory policies. These requirements mean that the regulatory suitability of a supplied ingredient must be evaluated individually rather than assumed from the manufacturer’s European location or general pharmaceutical expertise.

Both frameworks also contain relevant requirements concerning bulk drug substance documentation and the regulatory status of manufacturing establishments. The FDA specifies that applicable substances must be accompanied by valid certificates of analysis and meet the relevant manufacturing-establishment registration requirements. EUROAPI’s commitment to provide available technical and regulatory information could support customers in assessing ingredient suitability and complying with their obligations. However, compliance with European manufacturing requirements does not automatically establish that a particular substance is authorised for every intended compounding application in the United States.

Recent US regulatory developments illustrate the difficulty of extrapolating commercial demand into legally available peptide supply opportunities. In April 2026, the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the Section 503B bulk drug substances list after concluding that it had not identified the necessary clinical need for their inclusion. That proposal followed regulatory actions concerning compounded glucagon-like peptide-1 products and reflected closer scrutiny of circumstances in which compounded treatments are promoted as alternatives to approved medicines. These developments are relevant to the wider industry, but there is no disclosed basis for suggesting that the MEDISCA and EUROAPI agreement specifically covers those three ingredients.

The distinction between an API manufactured under a pharmaceutical quality system and a finished compounded medicine is equally important. The FDA does not approve compounded drug products before marketing in the same manner as approved medicines, and manufacturing quality is only one element of the applicable patient-safety framework. The clinical appropriateness of a particular compounded treatment, the legal eligibility of its ingredients and the controls used by the compounder remain separate considerations. An ingredient partnership can strengthen sourcing and documentation without independently establishing the safety, effectiveness or regulatory permissibility of a finished compounded product.

How have EUROAPI shares performed as the company looks for new commercial growth opportunities?

EUROAPI shares closed at €0.772 on Euronext Paris on October 9, 2026, gaining 3.21% during the session. The stock had advanced 1.20% on October 7, when the MEDISCA announcement was distributed, before declining 1.06% in the following session. These movements indicate a mixed short-term trading pattern rather than an established market reassessment attributable to the partnership. Over the preceding four-week period, the stock remained approximately 5% lower, consistent with continued caution surrounding the company’s operating performance.

The broader valuation picture is substantially more challenging. EUROAPI’s October 9 closing price was approximately 77% below its 52-week high of €3.388 and remained relatively close to its 52-week low of €0.713. Its market capitalisation stood at approximately €73.8 million, reflecting a heavily discounted equity valuation relative to the scale of its reported annual revenue. That difference should not be interpreted as evidence of undervaluation on its own because enterprise value, future cash requirements, restructuring commitments and the trajectory of operating profitability all influence the residual value attributable to shareholders.

The MEDISCA agreement may improve the quality of EUROAPI’s commercial opportunity set, particularly if it generates repeat orders from customers that were previously difficult to access. Nevertheless, a distribution framework without disclosed revenue commitments provides limited evidence for changing near-term earnings estimates. A more durable improvement in sentiment would likely require stronger API order intake, stabilisation of manufacturing profitability and reduced cash consumption. The partnership is therefore a potential contributor to an operating recovery rather than a demonstrated financial turning point.

What milestones will determine whether the MEDISCA and EUROAPI partnership delivers sustainable growth?

The first tangible indicator will be the range of EUROAPI-manufactured ingredients that MEDISCA actually makes available to North American compounders. Publishing a defined product offering, supported by relevant quality information and clear distribution arrangements, would demonstrate that the initial commercial framework is translating into market access. The subsequent measure would be recurring purchasing activity, particularly if it broadens EUROAPI’s customer exposure without compromising profitability. The companies have not announced a timetable for product additions, a quantified sales target or a forecast contribution from the partnership.

The peptide opportunity will require a separate evaluation because development and manufacturing capabilities do not automatically establish a commercially addressable compounding market. Specific ingredients, intended applications, regulatory eligibility and customer needs will determine which opportunities can progress from discussions into operational programmes. MEDISCA’s dedicated peptide division provides an organisational structure for pursuing such opportunities, while EUROAPI offers potential pharmaceutical manufacturing expertise. The existence of these complementary capabilities supports further investigation, but not an assumption that peptide collaboration will develop into a material revenue stream.

For EUROAPI, the agreement fits a broader effort to rebuild a more resilient commercial portfolio during an operational restructuring. For MEDISCA, it extends a manufacturer-led sourcing strategy that could strengthen ingredient access and technical support for compounding customers. The most convincing evidence of success would combine actual API availability, repeat customer demand and improving manufacturing economics, with any peptide expansion supported by clearly identified products and appropriate regulatory pathways. Until those measures emerge, the partnership is best understood as a strategically relevant distribution initiative whose financial impact remains to be established.

Key takeaways from the MEDISCA and EUROAPI pharmaceutical API partnership

• EUROAPI has appointed MEDISCA as its first strategic distribution partner specifically focused on the North American pharmaceutical compounding market.
• The partnership includes exclusive supply arrangements for selected European-manufactured APIs, although individual products and commercial values remain undisclosed.
• MEDISCA’s manufacturer-led sourcing strategy follows its May 2026 pharmaceutical-grade vitamin API partnership with dsm-firmenich.
• The agreement follows the September 2026 creation of MEDISCA Peptides, providing a potential platform for future peptide-related cooperation.
• EUROAPI’s API Solutions revenue declined 19.3% to €241.9 million in the first half of 2026.
• EUROAPI reported a €141.5 million first-half net loss, alongside weaker core EBITDA and negative cash flow.
• US pharmaceutical compounding rules restrict which bulk substances may legally be used, independently of ingredient manufacturing quality.
• EUROAPI shares closed at €0.772 on October 9, remaining approximately 77% below their 52-week high.
• The next commercial evidence will be disclosed products, sustained customer orders and measurable contributions to EUROAPI’s operating performance.